1m Children Targetted As Nigeria Gets First-ever Meningitis Vaccine

Nigeria has become the first country to receive the new MenFive vaccine from the Gavi-funded global stockpile, with a shipment delivered by the United Nations Children‘s Fund (UNICEF).
Gavi, in a statement made available to LEADERSHIP Friday, yesterday, said the doses will be used to respond to an on-going meningococcus C outbreak, targeting to vaccinate around a million children in six local government areas in Jigawa State: Babura, Birniwa, Gagarawa, Gumel, Maigatari, and Sule Tankarkar.

The statement noted that the MenFive vaccine, developed through a 13-year collaboration between PATH and Serum Institute of India, with support from the UK government’s Foreign, Commonwealth and Development Office, received the World Health Organisation (WHO) prequalification in July 2023.
It said the vaccine protects against the five main serogroups of meningococcal meningitis impacting Africa – meningococcal serogroups A, C, W, Y, and X. It is the only vaccine that protects against serogroup X.

Meningitis, according to WHO is transmitted from person to person through droplets of respiratory and throat secretions, is an infection of the meninges, the thin lining that surrounds the brain and spinal cord.
The disease is known to cause hearing loss, brain damage, seizures, limb loss or other disabilities and death, and can also be triggered by viruses, fungi or parasites.
Gavi said this first shipment signals the start of its support for a multivalent meningococcal conjugate vaccine (MMCV) programme, which will see the MenFive vaccine rolled out through outbreak response, routine immunisation, and catch-up campaigns in high-risk countries.

“Over the years, Gavi has worked with countries to support vaccination against meningitis A, reaching nearly 400 million children through campaigns and routine immunisation. These efforts have helped Africa defeat meningitis A, with no new cases detected since 2017. The addition of MenFive into health systems’ toolkit holds out the possibility that the other circulating serogroups could also one day be defeated,” said Gavi.
Commenting on this milestone, the director of High Impact Countries at Gavi, the Vaccine Alliance, Dr Tokunbo Oshin, said, “With outbreaks of infectious diseases on the rise worldwide, new innovations such as MenFive are critical in helping us fight back.

Thanks to vaccines, we have eliminated large and disruptive outbreaks of meningitis A in Africa: now we have a tool to respond to other meningococcal meningitis serogroups that still cause large outbreaks resulting in long-term disability and deaths.

Gavi will be working closely with the Nigerian government as well as our partners such as UNICEF and WHO to support the response to this outbreak.”
Gavi, the Vaccine Alliance funds the global stockpiles of vaccines against cholera, Ebola, meningitis and yellow fever, and supports outbreak response campaigns in lower-income countries.